Press Releases Events & Presentations Event Details AASLD 2017 Washington, DC Oct 22, 2017 Supporting Materials Rapid Turnover of cccDNA in Chronic Hepatitis B Patients Who Have Failed Nucleoside Treatment Due to Emerging Resistance 1.5 MB Phase 1a Safety and Pharmacokinetics of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM) For the Treatment of Chronic HBV Infection 1.1 MB Profile of Potent Second Generation CpAMs Capable of Inhibiting the Generation of HBsAg, HBeAg, pgRNA and cccDNA in HBV Infected Cells 2.2 MB Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
AASLD 2017 Washington, DC Oct 22, 2017 Supporting Materials Rapid Turnover of cccDNA in Chronic Hepatitis B Patients Who Have Failed Nucleoside Treatment Due to Emerging Resistance 1.5 MB Phase 1a Safety and Pharmacokinetics of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM) For the Treatment of Chronic HBV Infection 1.1 MB Profile of Potent Second Generation CpAMs Capable of Inhibiting the Generation of HBsAg, HBeAg, pgRNA and cccDNA in HBV Infected Cells 2.2 MB
Rapid Turnover of cccDNA in Chronic Hepatitis B Patients Who Have Failed Nucleoside Treatment Due to Emerging Resistance 1.5 MB
Phase 1a Safety and Pharmacokinetics of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM) For the Treatment of Chronic HBV Infection 1.1 MB
Profile of Potent Second Generation CpAMs Capable of Inhibiting the Generation of HBsAg, HBeAg, pgRNA and cccDNA in HBV Infected Cells 2.2 MB